Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 10/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.40 |
| ▸ | CTRC | Q99895 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552413 | 0.80 | MMP2 (0.49) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5558773 | 0.80 | DPP4 (0.66) | ACEDPP4DPP8DPP9F10 | |
| SCHEMBL6163357 | 0.78 | CTSL (0.60) | CTSLCTSSCTSKCYP3A4CALCRL | |
| SCHEMBL6163361 | 0.78 | CTSL (0.60) | CTSLCTSSCTSKCYP3A4CALCRL | |
| SCHEMBL3599165 | 0.76 | CTSS (0.76) | CTSLCTSSCTSKACE | |
| SCHEMBL29908025 | 0.76 | CTSS (0.76) | CTSLCTSSCTSKACE | |
| SCHEMBL29828648 | 0.76 | CTSS (0.76) | CTSLCTSSCTSKACE | |
| SCHEMBL999046 | 0.76 | CTSS (0.76) | CTSLCTSSCTSKACE | |
| SCHEMBL999047 | 0.76 | CTSS (0.76) | CTSLCTSSCTSKACE | |
| SCHEMBL6807070 | 0.76 | CMA1 (0.55) | CMA1CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | CTSL 226/4885CTSS 596/4885CTSK 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.